What is the revenue and EPS growth rate for BioLife Solutions year over year?

What were the key takeaways from BioLife Solutions's earnings call?

What does BioLife Solutions do and what are its main business segments?

Did BioLife Solutions beat or miss consensus estimates last quarter?

What is the market's earnings forecast for BioLife Solutions next quarter?

What is BioLife Solutions's gross profit margin?

What is BioLife Solutions's latest dividend and current dividend yield?

What were the key takeaways from BioLife Solutions’s earnings call?

- **Revenue Growth**: 29% YoY to $96 million in 2025, driven by biopreservation media (BPM) with 85% Q4 contribution.
- **Strategic Expansion**: New QKine partnership for cytokines and cross-selling initiative targeting 3x revenue per patient dose.
- **2026 Guidance**: $112-115 million revenue (17-20% growth), first GAAP net income, and 2-3ppt margin improvement from resolved bag yield issues.
- **CGT Market Leadership**: 70% share in Phase III+ trials, embedded in 16 approved therapies, and 250+ trials.
- **Operational Focus**: ERP implementation and CryoCase adoption to reduce costs and improve margins in 2026.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue for 2025 reached $96 million, up 29% YoY, driven by biopreservation media (BPM) demand. Q4 revenue was $24.8 million, a 20% YoY increase.
- **Market Leadership**: BPM accounted for 85% of Q4 revenue, with 80% from top 20 customers. Direct commercial customers now represent ~50% of revenue, up from low 40s in 2024.
- **Strategic Initiatives**: 
  - Cross-selling of cell processing tools to existing BPM customers aims to triple revenue per patient dose.
  - New partnership with QKine for cytokine distribution and co-packaging in CellSeal vials, targeting CGT adjacencies.
  - 2026 guidance: $112-115 million revenue (17-20% growth), first GAAP net income in years.
- **CGT Market Outlook**: Expect 5+ unique therapy approvals in 2026, with BioLife embedded in 16 approved therapies and 250+ trials (70% share in Phase III+).

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Adjusted EBITDA: $6.9 million (28% of revenue), up from $3.7 million (18% of revenue) in Q4 2024.
  - Gross margin: 64% (down 3ppt YoY due to bag yield issues).
  - Cash balance: $120.2 million, up $23.5 million from SAVSU divestiture.
- **2025 Full Year**: 
  - Adjusted EBITDA: $25 million (26% of revenue), up from $13.3 million (18% of revenue).
  - GAAP net loss narrowed to $1.9 million (Q4) and $6.3 million (full year).
- **2026 Outlook**: 
  - Gross margin ~mid-60s, flat vs. 2025 due to higher ASPs offset by product mix.
  - Operating expenses to grow with R&D and sales investments.

**【Q&A Highlights】**
- **Bag Yield Impact**: 2-3ppt margin headwind in 2025H2, resolved with new manufacturing process. Full benefit expected Q4 2026 after inventory sell-through.
- **Commercial vs. Clinical Mix**: 50-55% commercial revenue expected in 2026, with clinical demand constrained by small biotech funding.
- **CryoCase Adoption**: 18-24 months to replace bags with rigid containers, reducing scrap and improving margins.
- **QKine Partnership**: Exclusivity on certain cytokines, with co-packaging development for 2026H2. Longer-term potential for broader collaboration.
- **Cross-Sell Progress**: Non-BPM tools growing faster than BPM, with ~80% of growth tied to existing BPM customers.


BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 cell processing revenue up 33% YoY to $25.4 million, with 50% from commercial customers.
- **Margin Expansion**: Adjusted EBITDA margin 28% (vs. 23% prior year), driven by operating leverage.
- **2026 Outlook**: 4-6% price increases planned; cross-sell opportunities could double revenue per customer.
- **Strategic Focus**: $25M evo sale strengthens balance sheet; $125M cash for disciplined M&A in adjacencies.
- **Key Risk**: 2026 guidance reliant on Phase III trial approvals, with 80% of trials using BioLife media.

**【Management Opening Remarks】**
- CEO Rod de Greef highlighted a 33% year-over-year increase in cell processing revenue, driven by biopreservation media (BPM) sales and a shift to direct commercial customers.
- CFO Troy Wichterman announced the sale of the evo Cold Chain product line for $25 million, bringing total cash to $125 million and enabling a more focused portfolio.
- Full-year 2025 revenue guidance raised to $95-96 million (27-29% growth), with cell processing guidance updated to $93-94 million (26-28% growth).

**【CEO Commentary】**
- Q3 cell processing revenue reached $25.4 million, with 80% from BPM and 50% from commercial customers. Adjusted EBITDA margin expanded to 28% (vs. 23% prior year).
- Direct sales mix increased to 70% (from 60%), reflecting stronger commercial customer relationships.
- Cross-selling opportunity: additional cell processing tools (e.g., CryoCase) could double/triple revenue per customer, with 6 dedicated sales reps focused on top 20 customers.
- 2026 outlook: 4-6% price increases planned, with focus on clinical trial adoption and commercial pipeline growth.

**【CFO Financial Commentary】**
- Q3 revenue: $28.1 million (31% YoY), driven by $1.3 million early BPM shipment.
- Adjusted EBITDA: $7.8 million (28% margin), up from $5 million (23% margin) in Q3 2024.
- Gross margin: 64% (down 3pp YoY due to one-time $600k inventory reserve).
- Balance sheet: $98.4 million cash post-evo sale, with $7.5 million SVB debt maturing in June 2026.

**【Q&A Highlights】**
- **Pricing**: 2026 price increases of 4-6% to offset input costs, with no immediate pass-through for Q3 list price hikes.
- **Sales Team**: Cautious expansion (1-2 reps in 2026) focused on high-margin cross-sell opportunities.
- **Clinical Trials**: 80% of Phase III trials use BioLife media; government funding delays minimal impact on Q4 guidance.
- **Capital Allocation**: $125 million cash to pursue adjacencies with minimal financial risk, e.g., CryoCase automation for large customers.
- **ThawSTAR**: Retained as high-margin, complementary product with minimal marketing effort.

BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 29% YoY to $25.4 million, with cell processing revenue at $23 million (+28% YoY).
- **Margin Expansion**: Adjusted EBITDA margin improved 400bps to 24%, driven by operational efficiency.
- **Strategic Investments**: $2 million Pluristyx investment for iPSC assays; CryoCase adoption in evaluation by 30+ customers.
- **Guidance Update**: Full-year cell processing guidance raised to $91-93 million (24-26% growth), supported by 80% visibility from top 20 customers.
- **PanTHERA Progress**: Gen 2 molecule in testing with 2 commercial customers, with commercial launch expected H2 2026.
- **M&A Focus**: Disciplined approach to adjacencies like assays; Pluristyx acquisition option tied to revenue milestones.

**【CEO Summary Section】**
- Q2 2025 revenue reached $25.4 million, up 29% YoY, driven by 28% growth in cell processing revenue ($23 million) and 400bps EBITDA margin expansion to 24%.
- $100.2 million cash balance supports strategic investments, including $2 million in Pluristyx for iPSC-based assays and cross-selling opportunities (e.g., CT-5 adoption by top pharma customer).
- Raised full-year cell processing guidance to $91-93 million (24-26% growth) amid macro uncertainty, with 80% of BPM revenue tied to top 20 customers.
- Biopreservation media (BPM) maintains 70%+ share in 250+ CGT trials, including 30 Phase III trials (80% share), with 40% of revenue from approved therapies.
- CryoCase adoption in evaluation by 30+ customers, with key pharma customer seeking design changes for clinical pipeline.

**【CFO Financial Commentary】**
- GAAP net loss: $15.8 million (-$0.33 EPS), driven by $15.5 million non-cash IPR&D expense from PanTHERA acquisition.
- Adjusted EBITDA: $6.1 million (24% of revenue), up from $3.9 million (20% of revenue) in Q2 2024.
- Full-year guidance updated to $100-103 million total revenue (22-25% growth), with cell processing at $91-93 million and evo/Thaw at $9-10 million.
- 2025 adjusted gross margin expected in mid-60s, with no PanTHERA revenue contribution.

**【Q&A Key Highlights】**
- **Guidance Visibility**: 80% of BPM revenue from top 20 customers provides visibility for H2 2025, though lumpiness possible between Q3/Q4.
- **Cross-Selling Progress**: 30+ customers evaluating CryoCase; pharma customer close to adopting CT-5 for 2 commercial therapies.
- **PanTHERA Update**: Gen 2 molecule in hands of 2 commercial customers for efficacy testing, with commercial launch expected H2 2026.
- **M&A Strategy**: Disciplined focus on adjacencies (e.g., assays) and market leadership; Pluristyx investment includes option to acquire upon revenue milestones.
- **evo/Thaw Outlook**: Thaw maintained as core product; evo under strategic review for long-term fit.
- **Early-Stage Trends**: All segments up YoY, but Phase I/II clinical customers show softness (lightest growth segment).

BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 30% YoY to $23.9M, driven by 33% growth in cell processing platform.
- **Profitability Improves**: Adjusted EBITDA margin expands to 24%, up from 14% in Q1 2024.
- **Strategic Acquisition**: PanTHERA deal adds IRI technology for next-gen cryopreservation solutions, targeting -80°C logistics.
- **Guidance Confirmed**: Full-year 2025 revenue of $95.5M-$99M reflects 16%-20% growth, with 18%-21% from cell processing.
- **Risk Mitigation**: Minimal tariff exposure; distributors expect Chinese subsidies to offset costs in Europe.


**【CEO Summary Section】**
- Q1 2025 revenue reached $23.9 million, up 30% YoY, driven by a 33% increase in cell processing platform revenue.
- Adjusted EBITDA margin expanded to 24% (vs. 14% in Q1 2024), reflecting operational leverage from optimized portfolio and streamlined operations.
- Cell processing revenue grew sequentially for the 6th consecutive quarter, with 40% of BPM revenue from commercial therapy customers.
- Acquired PanTHERA CryoSolutions to enhance biopreservation portfolio with Ice Recrystallization Inhibitor (IRI) technology, positioning for long-term growth in cryopreservation solutions.
- Full-year 2025 revenue guidance reaffirmed at $95.5M-$99M, with 16%-20% growth driven by cell processing platform.

**【CFO Financial Commentary】**
- GAAP net loss of $0.4M ($0.01/share) vs. $3.2M ($0.07/share) in Q1 2024, driven by $3.5M improvement in gross margin.
- Adjusted EBITDA of $5.7M (24% of revenue) vs. $2.6M (14% of revenue) in Q1 2024.
- Cash balance of $107.6M as of March 31, 2025, supporting capital deployment and debt repayment ($2.5M quarterly).
- 2025 adjusted gross margin expected in mid-60s, with R&D expenses increasing by $1M due to PanTHERA-related costs.

**【Q&A Key Highlights】**
- Clinical demand trends stable, with distributors signaling no near-term slowdown despite NIH funding concerns.
- PanTHERA's IRI technology could enable cryopreservation at -80°C (dry ice) vs. -196°C (LN2), reducing logistics complexity.
- Pricing strategy adjustments with key customers will contribute ~$1M annualized by Q4 2025, with full impact over 3 years.
- Tariff exposure minimal due to U.S.-based manufacturing; distributors expect Chinese government subsidies to offset costs.
- Indianapolis facility expansion planned for 2026 to support hPL manufacturing and business continuity.
- No material revenue expected from PanTHERA in 2025; commercial adoption of new cryopreservation products likely 18+ months out.


BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript

- **2024 Transformation**: Divestitures drove 62% GAAP gross margin and $16M positive EBITDA, up from -$5M in 2023. 
- **2025 Growth**: $95.5-$99M revenue target (+16-20%), with cell processing platform leading at 18-21% growth. 
- **Margin Expansion**: EBITDA margin to mid-20s in 2025, with potential for 30%+ by 2026. 
- **Cross-Sell Opportunity**: CryoCase adoption could triple revenue per patient dose for key customers. 
- **Key Risks**: NIH funding uncertainty could impact academic research demand.

**【CEO Business Overview】**
- 2024 was a transformative year with total revenue of $82 million (down 43% YoY due to divestitures), but GAAP gross margin doubled to 62% and adjusted EBITDA turned positive at $16 million (19% of revenue). 
- Cell processing platform revenue grew 12% YoY to $74 million, driven by biopreservation media (BPM) and tools. Q4 cell processing revenue was $20.3 million (+37% YoY). 
- 2025 guidance: Total revenue $95.5-$99 million (+16-20%), with cell processing platform growing 18-21% to $86.5-$89 million. 
- Key growth lever: Cross-selling CryoCase vials and automated fill systems to existing BPM customers, which could increase revenue per patient dose by 2-3x. 

**【CFO Financial Highlights】**
- Q4 2024 revenue: $22.7 million (+31% YoY), with 60% GAAP gross margin and $4 million adjusted EBITDA. 
- 2024 cash balance: $109 million (vs $45 million in 2023) after divestitures, with $15 million remaining on bank debt. 
- 2025 outlook: Mid-60s adjusted gross margin, expanding EBITDA margin to mid-20s, and reduced GAAP net loss. 

**【Q&A Key Takeaways】**
1. **Margin Expansion**: 2025 EBITDA margin expected to improve steadily to mid-20s, driven by higher revenue and lower one-time costs. 
2. **Cross-Selling Progress**: 1 commercial customer already using CryoStor + CryoCase, with multiple others in evaluation. 
3. **Growth Catalysts**: 8 potential approvals/indications expansions in 2025, plus price increases (~mid-single digits). 
4. **Long-Term Vision**: 30%+ EBITDA margin achievable by 2026 if media revenue grows ~15% annually with 65% margin flow-through.

Actual											1.0617	-0.7	-0.04	-0.06	-0.03	0.19	0	-0.37	-0.17	-1.71	-0.23	-1.15	-0.32	-0.23	-0.67	-0.3	-0.22	-0.16	-0.04	-0.04	-0.01	-0.33	0.01	0.22
Forecast											-0.0275	-0.0329	-0.0157	-0.0163	-0.0383	-0.0413	-0.0857	-0.1686	-0.26	-0.2089	-0.165	-0.1613	-0.2133	-0.21	-0.375	-0.3417	-0.306	-0.1383	-0.0783	-0.06	-0.0486	-0.0335	-0.0116	-0.012
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3960.73%	-2027.66%	-154.78%	-268.10%	+21.67%	+560.05%	+100.00%	-119.45%	+34.62%	-718.57%	-39.39%	-612.96%	-50.02%	-9.52%	-78.67%	+12.20%	+28.10%	-15.69%	+48.91%	+33.33%	+79.42%	-885.07%	+186.21%	+1933.33%

BLFS

BLFS fundamentals

BLFS Q4 2025 Earnings

Earnings Call

You can ask Aime

BLFS

BLFS fundamentals

BLFS Q4 2025 Earnings

Earnings Call

BLFS Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

BLFS Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

BLFS Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

BLFS Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

BLFS Earnings Call Summary for Q4/20248:00 AM on Mar 3, 2025

You can ask Aime